Clarity Pharmaceuticals Ltd

CHIA:CU6 Stock Report

Market Cap: AU$1.8b

Clarity Pharmaceuticals Valuation

Is CU6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CU6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CU6's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CU6's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CU6?

Key metric: As CU6 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CU6. This is calculated by dividing CU6's market cap by their current book value.
What is CU6's PB Ratio?
PB Ratio12.6x
BookAU$146.30m
Market CapAU$1.84b

Price to Book Ratio vs Peers

How does CU6's PB Ratio compare to its peers?

The above table shows the PB ratio for CU6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.7x
NEU Neuren Pharmaceuticals
7.2x-9.9%AU$1.6b
ALA Arovella Therapeutics
16.9xn/aAU$195.3m
MYX Mayne Pharma Group
0.9x110.0%AU$387.1m
BOT Botanix Pharmaceuticals
5.9x99.4%AU$645.2m
CU6 Clarity Pharmaceuticals
12.6x68.2%AU$1.8b

Price-To-Book vs Peers: CU6 is expensive based on its Price-To-Book Ratio (12.6x) compared to the peer average (7.8x).

Price to Book Ratio vs Industry

How does CU6's PB Ratio compare vs other companies in the AU Pharmaceuticals Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
LGP Little Green Pharma
0.5x110.1%US$26.42m
EOF Ecofibre
0.4xn/aUS$9.97m
CGB Cann Global
0.5xn/aUS$3.69m
ECS ECS Botanics Holdings
0.05xn/aUS$1.00m
No more companies available in this PB range
CU6 12.6xIndustry Avg. 4.4xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CU6 is expensive based on its Price-To-Book Ratio (12.6x) compared to the Australian Pharmaceuticals industry average (4.1x).

Price to Book Ratio vs Fair Ratio

What is CU6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CU6 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio12.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CU6's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CU6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$5.76
AU$8.89
+54.4%
8.9%AU$10.00AU$8.20n/a3
Nov ’25AU$6.76
AU$8.89
+31.6%
8.9%AU$10.00AU$8.20n/a3
Oct ’25AU$8.69
AU$8.89
+2.3%
8.9%AU$10.00AU$8.20n/a3
Sep ’25AU$7.24
AU$8.89
+22.8%
8.9%AU$10.00AU$8.20n/a3
Aug ’25AU$6.49
AU$7.30
+12.5%
30.8%AU$10.00AU$4.50n/a3
Jul ’25AU$5.15
AU$3.87
-24.9%
15.0%AU$4.50AU$3.10n/a3
Jun ’25AU$5.03
AU$3.87
-23.1%
15.0%AU$4.50AU$3.10n/a3
May ’25AU$3.00
AU$3.37
+12.4%
11.0%AU$3.90AU$3.10n/a3
Apr ’25AU$2.77
AU$3.35
+21.0%
11.6%AU$3.90AU$3.05n/a3
Mar ’25AU$2.72
AU$3.12
+14.5%
10.8%AU$3.45AU$2.78n/a2
Feb ’25AU$2.30
AU$2.48
+7.7%
34.9%AU$3.35AU$1.30n/a3
Jan ’25AU$1.90
AU$2.19
+15.7%
34.5%AU$3.15AU$1.30n/a3
Dec ’24AU$1.38
AU$2.00
+45.4%
41.0%AU$3.15AU$1.30n/a3
Nov ’24AU$1.02
AU$1.82
+78.9%
31.1%AU$2.60AU$1.30AU$6.763
Oct ’24AU$1.17
AU$1.82
+55.8%
31.1%AU$2.60AU$1.30AU$8.693
Sep ’24AU$1.03
AU$1.71
+65.7%
37.1%AU$2.60AU$1.22AU$7.243
Aug ’24AU$0.89
AU$1.67
+89.1%
35.0%AU$2.50AU$1.22AU$6.493
Jul ’24AU$0.70
AU$1.71
+143.1%
33.1%AU$2.50AU$1.22AU$5.153
Jun ’24AU$0.77
AU$1.71
+121.8%
33.1%AU$2.50AU$1.22AU$5.033
May ’24AU$0.74
AU$1.69
+127.0%
34.0%AU$2.50AU$1.22AU$3.003
Apr ’24AU$0.73
AU$1.69
+131.7%
34.0%AU$2.50AU$1.22AU$2.773
Mar ’24AU$0.91
AU$1.69
+86.9%
34.0%AU$2.50AU$1.22AU$2.723
Feb ’24AU$0.85
AU$1.69
+98.9%
34.0%AU$2.50AU$1.22AU$2.303
Jan ’24AU$0.98
AU$1.66
+68.2%
31.9%AU$2.40AU$1.22AU$1.903
Dec ’23AU$0.99
AU$1.41
+42.1%
50.2%AU$2.40AU$0.82AU$1.383
Nov ’23AU$0.69
AU$1.41
+102.4%
50.2%AU$2.40AU$0.82AU$1.023

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.32

7D

-16.8%

1Y

-18.7%

AVITA Medical

US$343.1m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

7D

5.0%

1Y

16.4%

AVITA Medical

US$343.1m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.98

7D

5.0%

1Y

16.4%